StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Down 25.5 %
Bellerophon Therapeutics stock opened at $0.01 on Friday. The firm has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The business’s 50-day moving average price is $0.03 and its 200 day moving average price is $0.04.
Bellerophon Therapeutics Dividend Announcement
The company also recently disclosed a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were paid a dividend of $0.019 per share. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 117.8%.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Calculate Options Profits
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
